Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Clover Custom Blending LLC
WARNING LETTER
•Clover Custom Blending LLC•May 17, 2017

Clover Custom Blending LLC – FDA Warning Letter, May 17, 2017

Record Details

The FDA inspected Clover Custom Blending LLC from May 15-17, 2017, identifying significant Current Good Manufacturing Practice (CGMP) violations for finished pharmaceuticals, rendering drug products adulterated (21 U.S.C. 351(a)(2)(B)) and one product misbranded (21 U.S.C. 352(c)). Key deficiencies included the firm's failure to thoroughly investigate out-of-specification (OOS) results for sunscreen lotion (21 CFR 211.192), such as super-potent and sub-potent active ingredients, before product release. The quality control unit lacked established written responsibilities and procedures for critical operations like training, batch record completion, recalls, complaints, deviations, and investigations (21 CFR 211.22(d)). The facility also failed to maintain adequate separate areas, using shared equipment for OTC drugs and industrial products, leading to potential cross-contamination, with observations of flaking paint and unknown residues (21 CFR 211.42(c)). Furthermore, the firm did not conduct identity testing for each drug component or validate supplier analyses (21 CFR 211.84(d)(1)&(2)). The Bulk SPF 30 Sunscreen Tote was deemed misbranded because its outer container labeling lacked required "Drug Facts" (21 CFR 201.66). The FDA deemed the firm's initial response inadequate and strongly recommended engaging a CGMP consultant. Clover Custom Blending must promptly correct these violations, provide comprehensive corrective and preventive action plans, and conduct risk assessments for affected products within 15 working days to avoid further legal action, including seizure, injunction, and impact on drug approvals or export certificates.

Company
Clover Custom Blending LLC
Inspection date
May 17, 2017
Product type
Drugs
Office
Dallas District Office
People
  • Monica R. Maxwell (Program Division Director)
  • Mary L. Mayleben (Pharmaceutical Program Manager)
View Company Profile

ID · 4bb36bbb-06b0-4064-b00a-09e9877a6976

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 211FD&C Act 501(a)(2)(B)FD&C Act 502(c)21 U.S.C. 352(c)21 CFR 211.19221 CFR 211.22(d)21 CFR 211.42(c)21 CFR 211.84(d)(1)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Clover Custom Blending LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.